Get the Stockscreener App
1.32
4.76%
0.06
After Hours:
1.28
-0.04
-3.03%
Inmune Bio Inc stock is traded at $1.32, with a volume of 305.07K.
It is up +4.76% in the last 24 hours and up +0.76% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
305.07K
Relative Volume:
0.72
Market Cap:
$35.09M
Revenue:
$50,000
Net Income/Loss:
$-45.93M
P/E Ratio:
-0.686
EPS:
-1.9241
Net Cash Flow:
$-23.62M
1W Performance:
+2.33%
1M Performance:
+0.76%
6M Performance:
-31.61%
1Y Performance:
-82.33%
1-Day Range:
$1.255
$1.33
1-Week Range:
$1.155
$1.33
52-Week Range:
$1.09
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.32 | 33.50M | 50,000 | -45.93M | -23.62M | -1.9241 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INMune Bio, Inc. (NASDAQ:INMB) Q4 2025 earnings call transcript - MSN
Options Flow: Does INmune Bio Inc have a competitive edge2026 Macro Impact & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Aug Highlights: What is the earnings history of INmune Bio IncBond Market & Community Consensus Stock Picks - baoquankhu1.vn
Lucid Capital Markets upgrades INmune Bio (INMB) - MSN
Analysis Recap: Whats the RSI of INmune Bio Inc stock2026 Trade Ideas & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Inmune Bio Inc stock: What investors need to know about its biotech potential now - AD HOC NEWS
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - ADVFN
INmune Bio (INMB) price target increased by 33.33% to 7.14 - MSN
Support Test: Whats the RSI of INmune Bio Inc stockWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
INMB.O PE Ratio & Valuation, Is INMB.O Overvalued - Intellectia AI
INmune Bio, Inc. (NASDAQ:INMB) Q4 2025 Earnings Call Transcript - Insider Monkey
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely - Yahoo Finance
Inmune Bio Earnings Call Balances Progress and Risk - The Globe and Mail
S P Trends: Whats the profit margin of INmune Bio IncWeekly Trade Report & Weekly Stock Performance Updates - baoquankhu1.vn
INmune Bio, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - Moomoo
Inmune Bio Inc Stock: Recent 2025 Results Highlight Late-Stage Pipeline Progress Amid Cash Runway to - AD HOC NEWS
INmune Bio reports $45.9M loss, plans UK regulatory filing By Investing.com - Investing.com South Africa
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
INmune Bio Q4 2025 Earnings Call Transcript - MarketBeat
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategi - GuruFocus
INmune Bio Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: INmune Bio highlights CORDStrom progress in Q4 2025 - Investing.com Canada
INmune Bio | 10-K: FY2025 Annual Report - Moomoo
INMB: CORDStrom nears regulatory filings as cash runway extends to Q1 2027 after $27.5M raised - TradingView
Pipeline reset at INmune Bio (NASDAQ: INMB) after CORDStrom gains and XPro setback - Stock Titan
INmune Bio reports $45.9M loss, plans UK regulatory filing - Investing.com
INmune Bio Inc. Announces 2025 Results and Provides Business Update - The Manila Times
INmune Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Squeeze: Will INmune Bio Inc outperform tech stocksTrade Performance Summary & Fast Gain Stock Tips - baoquankhu1.vn
INMune Bio FY 2025 earnings preview - MSN
INmune Bio Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
INmune Bio Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
INMB Technical Analysis | Trend, Signals & Chart Patterns | INMUNE BIO INC (NASDAQ:INMB) - ChartMill
INmune Bio (INMB.US) will release its earnings report after the market close on March 30. - Moomoo
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - The Manila Times
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on ... - Bluefield Daily Telegraph
INmune Bio will discuss 2025 results and corporate update March 30 - stocktitan.net
Market Moves: Whats the RSI of INmune Bio Inc stock2026 Buyback Activity & Low Drawdown Investment Ideas - baoquankhu1.vn
If You Invested $1,000 in Inmune Bio Inc (INMB) - Stock Titan
Block Trades: How does INmune Bio Inc compare to its peersMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
INMB PE Ratio & Valuation, Is INMB Overvalued - Intellectia AI
INMB Showcases Advancements in Alzheimer's Treatment at AD/PD 20 - GuruFocus
INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s - TipRanks
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease - The Manila Times
Alzheimer’s trial gets plenary spotlight as blood markers guide treatment - Stock Titan
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):